MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
14.33
+0.13
+0.92%
After Hours: 14.99 +0.66 +4.61% 17:51 12/05 EST
OPEN
14.26
PREV CLOSE
14.20
HIGH
14.75
LOW
14.08
VOLUME
69.06K
TURNOVER
--
52 WEEK HIGH
18.71
52 WEEK LOW
5.01
MARKET CAP
103.32M
P/E (TTM)
6.53
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATRA last week (1124-1128)?
Weekly Report · 5d ago
Atara Biotherapeutics: An Empty Pipeline With Little Gas
Seeking Alpha · 6d ago
Weekly Report: what happened at ATRA last week (1117-1121)?
Weekly Report · 11/24 10:20
ATARA BIOTHERAPEUTICS INC <ATRA.O>: MIZUHO RAISES TARGET PRICE TO $18 FROM $16
Reuters · 11/21 11:33
Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
TipRanks · 11/20 19:45
Top Executives Make Significant Moves with Atara Biotherapeutics Stock!
TipRanks · 11/20 02:12
Atara Biotherapeutics Chief Accounting Officer Yanina Grant-Huerta Reports Disposal of Common Shares
Reuters · 11/19 21:55
Weekly Report: what happened at ATRA last week (1110-1114)?
Weekly Report · 11/17 10:20
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.